Safety and efficacy of depatuxizumab mafodotin + temozolomide in patients with EGFR-amplified, recurrent glioblastoma: results from an international phase I multicenter trial

Abstract Background Patients with glioblastoma (GBM) have a dismal prognosis. Nearly all will relapse with no clear standard of care for recurrent disease (rGBM). Approximately 50% of patients have tumors harboring epidermal growth factor receptor (EGFR) amplification. The antibody–drug conjugate depatuxizumab mafodotin (depatux-m) binds cells with EGFR amplification, is internalized, and releases a microtubule toxin, killing the cell. Here we report efficacy, safety and pharmacokinetics (PK) of depatux-m + temozolomide (TMZ) in patients with EGFR-amplified rGBM. Methods M12-356 (NCT01800695) was an open-label study encompassing patients with newly diagnosed or rGBM across 3 treatment arms. Results are reported for adults with EGFR-amplified, measurable rGBM who received depatux-m (0.5–1.5 mg/kg) on days 1 and 15, and TMZ (150–200 mg/m2) on days 1–5 in a 28-day cycle. Patients were bevacizumab and nitrosourea naïve. Results There were 60 patients, median age 56 years (range, 20–79). Fifty-nine patients previously received TMZ. Common adverse events (AEs) were blurred vision (63%), fatigue (38%), and photophobia (35%). Grades 3/4 AEs were split between ocular and non-ocular AEs, occurring in 22% of patients each. Systemic PK exposure of depatux-m was dose proportional. The objective response rate was 14.3%, the 6-month progression-free survival rate was 25.2%, and the 6-month overall survival rate was 69.1%. Conclusions Depatux-m + TMZ displayed an AE profile similar to what was described previously. Antitumor activity in this TMZ-refractory population was encouraging. Continued study of depatux-m in patients with EGFR-amplified, newly diagnosed, or recurrent GBM is ongoing in 2 global, randomized trials (NCT02573324, NCT02343406).

[1]  M. J. van den Bent,et al.  Safety, pharmacokinetics, and antitumor response of depatuxizumab mafodotin as monotherapy or in combination with temozolomide in patients with glioblastoma , 2018, Neuro-oncology.

[2]  Martin Klein,et al.  Lomustine and Bevacizumab in Progressive Glioblastoma , 2017, The New England journal of medicine.

[3]  T. Cloughesy,et al.  PATH-35. MAINTENANCE OF EGFR ABNORMALITIES OVER TIME AND COMPARISON OF MOLECULAR METHODOLOGIES IN GLIOBLASTOMA (GBM) , 2017 .

[4]  M. Weller,et al.  LTBK-04 FIRST RESULTS OF THE RANDOMIZED PHASE II STUDY ON DEPATUX –M ALONE, DEPATUX-M IN COMBINATION WITH TEMOZOLOMIDE AND EITHER TEMOZOLOMIDE OR LOMUSTINE IN RECURRENT EGFR AMPLIFIED GLIOBLASTOMA: FIRST REPORT FROM INTELLANCE 2/EORTC TRIAL 1410 , 2017 .

[5]  M. Bent,et al.  ACTR-13. EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) AMPLIFICATION RATES OBSERVED IN SCREENING PATIENTS FOR RANDOMIZED CLINICAL TRIALS IN GLIOBLASTOMA , 2017 .

[6]  Hao Xiong,et al.  Efficacy of depatuxizumab mafodotin (ABT-414) monotherapy in patients with EGFR-amplified, recurrent glioblastoma: results from a multi-center, international study , 2017, Cancer Chemotherapy and Pharmacology.

[7]  M. Bent,et al.  327OEpidermal growth factor receptor (EGFR) amplification rates observed in screening patients for randomized clinical trials in glioblastoma , 2017 .

[8]  A. Brandes,et al.  Pharmacotherapy of Glioblastoma: Established Treatments and Emerging Concepts , 2017, CNS Drugs.

[9]  T. Mikkelsen,et al.  Efficacy analysis of ABT-414 with or without temozolomide (TMZ) in patients (pts) with EGFR-amplified, recurrent glioblastoma (rGBM) from a multicenter, international phase I clinical trial , 2017 .

[10]  M. J. van den Bent,et al.  Efficacy and safety results of ABT-414 in combination with radiation and temozolomide in newly diagnosed glioblastoma , 2016, Neuro-oncology.

[11]  G. Reifenberger,et al.  EGFR gene amplification and variant III (EGFRvIII) mutation in primary and recurrent glioblastoma. , 2016 .

[12]  M. Weller,et al.  Therapeutic options in recurrent glioblastoma--An update. , 2016, Critical reviews in oncology/hematology.

[13]  Kedar S Vaidya,et al.  ABT-414, an Antibody–Drug Conjugate Targeting a Tumor-Selective EGFR Epitope , 2016, Molecular Cancer Therapeutics.

[14]  M. J. van den Bent,et al.  Changes in the EGFR amplification and EGFRvIII expression between paired primary and recurrent glioblastomas. , 2015, Neuro-oncology.

[15]  A. Nademanee,et al.  Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial , 2015, The Lancet.

[16]  G. Shapiro,et al.  A phase 1 study of ABT-806 in subjects with advanced solid tumors , 2015, Investigational New Drugs.

[17]  A. Scott,et al.  Characterization of ABT-806, a Humanized Tumor-Specific Anti-EGFR Monoclonal Antibody , 2015, Molecular Cancer Therapeutics.

[18]  H. Ellis,et al.  Current Therapeutic Advances Targeting EGFR and EGFRvIII in Glioblastoma , 2015, Front. Oncol..

[19]  R. Vernhout,et al.  Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial. , 2014, The Lancet. Oncology.

[20]  Sung-Bae Kim,et al.  Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial. , 2014, The Lancet. Oncology.

[21]  K. Hoang-Xuan,et al.  Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. , 2014, The New England journal of medicine.

[22]  H. Gan,et al.  The epidermal growth factor receptor variant III (EGFRvIII): where wild things are altered , 2013, The FEBS journal.

[23]  D. Haussler,et al.  The Somatic Genomic Landscape of Glioblastoma , 2013, Cell.

[24]  W. Curran,et al.  RTOG 0211: a phase 1/2 study of radiation therapy with concurrent gefitinib for newly diagnosed glioblastoma patients. , 2013, International journal of radiation oncology, biology, physics.

[25]  Howard Colman,et al.  IDH1 and IDH2 Mutations in Gliomas , 2013, Current Neurology and Neuroscience Reports.

[26]  P. Kleihues,et al.  The Definition of Primary and Secondary Glioblastoma , 2012, Clinical Cancer Research.

[27]  S. Toms,et al.  Phase II trial of erlotinib with temozolomide and radiation in patients with newly diagnosed glioblastoma multiforme , 2010, Journal of Neuro-Oncology.

[28]  Susan M. Chang,et al.  Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  B. Neyns,et al.  Stratified phase II trial of cetuximab in patients with recurrent high-grade glioma. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[30]  R. Mirimanoff,et al.  Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. , 2009, The Lancet. Oncology.

[31]  M. J. van den Bent,et al.  Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  P. Mischel,et al.  A pilot study of everolimus and gefitinib in the treatment of recurrent glioblastoma (GBM) , 2009, Journal of Neuro-Oncology.

[33]  S. Horvath,et al.  Development of a Real-time RT-PCR Assay for Detecting EGFRvIII in Glioblastoma Samples , 2008, Clinical Cancer Research.

[34]  Stephen W Dusza,et al.  Dermatologic side effects associated with the epidermal growth factor receptor inhibitors. , 2006, Journal of the American Academy of Dermatology.

[35]  K. Aldape,et al.  A phase II study of bevacizumab and erlotinib after radiation and temozolomide in MGMT unmethylated GBM patients , 2015, Journal of Neuro-Oncology.

[36]  Susan M. Chang,et al.  A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy. , 2010, Neuro-oncology.

[37]  D. Gerber,et al.  The impact of thrombocytopenia from temozolomide and radiation in newly diagnosed adults with high-grade gliomas. , 2007, Neuro-oncology.